Effect of chronic intake of NSAIDs and cyclooxygenase 2 - Selective inhibitors on esophageal cancer incidence

Clinical Gastroenterology and Hepatology

Volumn 2, Issue 10, 2004, Pages 880-887

  Bardou, Marc ^a,b,c   Barkun, Alan N ^a   Ghosn, Joumana ^a   Hudson, Marie ^a   Rahme, Elham ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE BOURGOGNE   (France)

^c MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

AGED; ARTICLE; CANCER EPIDEMIOLOGY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; ESOPHAGUS CARCINOMA; FEMALE; GOVERNMENT; HUMAN; INSURANCE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CASE-CONTROL STUDIES; COHORT STUDIES; CYCLOOXYGENASE INHIBITORS; DATABASES; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; INCIDENCE; LACTONES; LOGISTIC MODELS; MALE; PYRAZOLES; QUEBEC; RISK FACTORS; SEX FACTORS; SULFONAMIDES; SULFONES;

EID: 5044230436     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-3565(04)00389-1     Document Type: Article

References (33)

1. A. Newnham, M.J. Quinn, P. Babb, J.Y. Kang, A. Majeed Trends in oesophageal and gastric cancer incidence, mortality and survival in England and Wales 1971-1998/1999 Aliment Pharmacol Ther 17 2003 655 664
2. S.S. Devesa, W.J. Blot, J.F. Fraumeni Jr Changing patterns in the incidence of esophageal and gastric carcinoma in the United States Cancer 83 1998 2049 2053
3. M. Younes, D.E. Henson, A. Ertan, C.C. Miller Incidence and survival trends of esophageal carcinoma in the United States racial and gender differences by histological type Scand J Gastroenterol 37 2002 1359 1365
4. J.M. Daly, L.H. Karnell, H.R. Menck National Cancer Data Base report on esophageal carcinoma Cancer 78 1996 1820 1828
5. C.W. Heath Jr, M.J. Thun, E.R. Greenberg, B. Levin, L.J. Marnett Nonsteroidal antiinflammatory drugs and human cancer report of an interdisciplinary research workshop Cancer 74 1994 2885 2888
6. E. Giovannucci, E.B. Rimm, M.J. Stampfer, G.A. Colditz, A. Ascherio, W.C. Willett Aspirin use and the risk for colorectal cancer and adenoma in male health professionals Ann Intern Med 121 1994 241 246
7. V.E. Steele, E.T. Hawk, J.L. Viner, R.A. Lubet Mechanisms and applications of non-steroidal anti-inflammatory drugs in the chemoprevention of cancer Mutat Res 523-524 2003 137 144
8. J.A. Baron Epidemiology of non-steroidal anti-inflammatory drugs and cancer Prog Exp Tumor Res 37 2003 1 24
9. E. Rahme, A.N. Barkun, Y. Toubouti, M. Bardou The cyclooxygenase-2-- selective inhibitors rofecoxib and celecoxib prevent colorectal neoplasia occurrence and recurrence Gastroenterology 125 2003 404 412
10. D.A. Corley, K. Kerlikowske, R. Verma, P. Buffler Protective association of aspirin/NSAIDs and esophageal cancer a systematic review and meta-analysis Gastroenterology 124 2003 47 56
11. G. Morgan Deleterious effects of prostaglandin E2 in oesophageal carcinogenesis Med Hypotheses 48 1997 177 181
12. E. Fosslien Molecular pathology of cyclooxygenase-2 in neoplasia Ann Clin Lab Sci 30 2000 3 21
13. M.B. Fennerty Does chemoprevention of Barrett's esophagus using acid suppression and/or COX-2 inhibition prevent neoplastic progression? Rev Gastroenterol Disord 2 suppl 2 2002 S30 S37
14. C.J. Buskens, B.P. Van Rees, A. Sivula, J.B. Reitsma, C. Haglund, P.J. Bosma, G.J. Offerhaus, J.J. Van Lanschot, A. Ristimaki Prognostic significance of elevated cyclooxygenase 2 expression in patients with adenocarcinoma of the esophagus Gastroenterology 122 2002 1800 1807
15. E. Rahme, L. Joseph, S.X. Kong, D.J. Watson, J. LeLorier Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients Br J Clin Pharmacol 52 2001 185 192
16. E. Rahme, L. Pilote, J. LeLorier Association between naproxen use and protection against acute myocardial infarction Arch Intern Med 162 2002 1111 1115
17. T.R. Koch The changing face of esophageal malignancy Curr Gastroenterol Rep 5 2003 187 191
18. E.I. Heath, P.J. Limburg, E.T. Hawk, A.A. Forastiere Adenocarcinoma of the esophagus risk factors and prevention Oncology (Huntingt) 14 2000 507 514 discussion 518-520, 522-523
19. C. Patrono, B. Coller, J.E. Dalen, G.A. FitzGerald, V. Fuster, M. Gent, J. Hirsh, G. Roth Platelet-active drugs the relationships among dose, effectiveness, and side effects Chest 119 2001 39S 63S
20. S. Friis, H.T. Sorensen, J.K. McLaughlin, S.P. Johnsen, W.J. Blot, J.H. Olsen A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin Br J Cancer 88 2003 684 688
21. C. Bosetti, R. Talamini, S. Franceschi, E. Negri, W. Garavello, C. La Vecchia Aspirin use and cancers of the upper aerodigestive tract Br J Cancer 88 2003 672 674
22. M.J. Thun, M.M. Namboodiri, E.E. Calle, W.D. Flanders, C.W. Heath Jr Aspirin use and risk of fatal cancer Cancer Res 53 1993 1322 1327
23. L. Sharp, C.E. Chilvers, K.K. Cheng, P.A. McKinney, R.F. Logan, P. Cook-Mozaffari, A. Ahmed, N.E. Day Risk factors for squamous cell carcinoma of the oesophagus in women a case-control study Br J Cancer 85 2001 1667 1670
24. D.C. Farrow, T.L. Vaughan, P.D. Hansten, J.L. Stanford, H.A. Risch, M.D. Gammon, W.H. Chow, R. Dubrow, H. Ahsan, S.T. Mayne, J.B. Schoenberg, A.B. West, H. Rotterdam, J.F. Fraumeni Jr, W.J. Blot Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 7 1998 97 102
25. D. Ratnasinghe, J. Tangrea, M.J. Roth, S. Dawsey, N. Hu, M. Anver, Q.H. Wang, P.R. Taylor Expression of cyclooxygenase-2 in human squamous cell carcinoma of the esophagus an immunohistochemical survey Anticancer Res 19 1999 171 174
26. C. Lagorce, F. Paraf, D. Vidaud, A. Couvelard, D. Wendum, A. Martin, J.F. Flejou Cyclooxygenase-2 is expressed frequently and early in Barrett's oesophagus and associated adenocarcinoma Histopathology 42 2003 457 465
27. C.D. Morris, G.R. Armstrong, G. Bigley, H. Green, S.E. Attwood Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence Am J Gastroenterol 96 2001 990 996
28. S. Kase, M. Osaki, S. Honjo, H. Adachi, S. Tsujitani, N. Kaibara, H. Ito Expression of cyclo-oxygenase-2 is correlated with high intratumoral microvessel density and low apoptotic index in human esophageal squamous cell carcinomas Virchows Arch 442 2003 129 135
29. N.S. Buttar, K.K. Wang, O. Leontovich, J.Y. Westcott, R.J. Pacifico, M.A. Anderson, K.K. Krishnadath, L.S. Lutzke, L.J. Burgart Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus Gastroenterology 122 2002 1101 1112
30. N.S. Buttar, K.K. Wang, M.A. Anderson, R.A. Dierkhising, R.J. Pacifico, K.K. Krishnadath, L.S. Lutzke The effect of selective cyclooxygenase-2 inhibition in Barrett's esophagus epithelium an in vitro study J Natl Cancer Inst 94 2002 422 429
31. B.S. Kaur, N. Khamnehei, M. Iravani, S.S. Namburu, O. Lin, G. Triadafilopoulos Rofecoxib inhibits cyclooxygenase 2 expression and activity and reduces cell proliferation in Barrett's esophagus Gastroenterology 123 2002 60 67
32. L. Vona-Davis, D.R. Riggs, B.J. Jackson, D.W. McFadden Anti-proliferative and apoptotic effects of rofecoxib on esophageal cancer in vitro J Surg Res 114 2003 276
33. E. Rahme, M.A. Marentette, S.X. Kong, J. Lelorier Use of NSAIDs, COX-2 inhibitors, and acetaminophen and associated coprescriptions of gastroprotective agents in an elderly population Arthritis Rheum 47 2002 595 602